



IPA and its subsidiaries are now MindWalk

## FY 2026 Earnings Presentation

# Q2

Presented by  
Dr. Jennifer Bath, CEO



Date: 12.15.25

## Disclosures

---

### Disclaimer

This presentation is not, & nothing in it should be construed as, an offer, invitation or recommendation in respect of MindWalk Holdings Corp. (the “Company”) securities, or an offer, invitation or recommendation to sell, or solicitation of an offer to buy, the facilities or of the Company’s securities in any jurisdiction. Neither this presentation nor anything in it shall form the basis of any contract or commitment. This presentation is not intended to be relied upon as advice to investors or potential investors & does not take into account the investment objectives, financial situation or needs of any investor. All investors should consider such factors in consultation with a professional advisor of their choosing when deciding if an investment is appropriate. The Company has prepared this presentation based on information available to it, including information derived from public sources that have not been independently verified. No representation or warranty, express or implied, is provided in relation to the fairness, accuracy, correctness, completeness or reliability of the information, opinions or conclusions expressed herein. These projections should not be considered a representation of the Company’s potential cash generation performance in any way.

### Forward Looking Statements

This presentation includes forward-looking statements (within the meaning of applicable securities laws) to provide prospective investors with information pertaining to the Company’s long-term business objective. Forward-looking statements often, but not always, are identified by the use of words such as “seek”, “anticipate”, “believe”, “plan”, “estimate”, “expect”, “targeting” and “intend” and statements that an event or result “may”, “will”, “should”, “could”, or “might” occur or be achieved and other similar expressions.

Forward-looking statements are not statements of historical fact or assurances of future performance. They are based on the current beliefs, expectations & assumptions of the Company’s management about the Company’s business, planned acquisitions, future plans, anticipated events & other future conditions. All forward-looking statements attributable to the Company or persons acting on its behalf apply only as of the date of this document & are expressly qualified in their entirety by the cautionary statements included in this presentation.

The forward-looking statements that are contained in this presentation involve a number of risks and uncertainties and are based on certain assumptions, including but not limited to: the progress, timing and costs related to the execution of the Company’s business plan and strategy; estimates and projections regarding the industry in which the Company operates; the future success of research and development activities; the absence of material changes in general business and economic conditions; estimates regarding the future financing and capital requirements; and the absence of adverse changes in relevant laws and regulations. As a consequence, actual results might differ materially from results forecast or suggested in these forward-looking statements. Please see the Company’s most recent Annual Information Form, which is available under the Company’s profile on EDGAR at [www.sec.gov/edgar](http://www.sec.gov/edgar) and SEDAR+ at [www.sedarplus.ca](http://www.sedarplus.ca) for additional related risks factors that could materially affect the Company’s operations and financial results.

Furthermore, forward-looking statements contained herein are made as of the date of this MD&A presentation and the Company disclaims any obligation to update any forward-looking statements, whether as a result of new information, future events or results or otherwise accept as required by applicable securities. There can be no assurance that forward-looking statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. Accordingly, readers should not place undue reliance on forward-looking statements.

Life Science Market Landscape

# Increased market focus on AI utilization in life sciences

Life science industry professionals

**2 out of 3**  
are AI/ML users

Large pharma, biotech firms and academia



Projected 2025 global data creation


**180**  
zettabytes

Genomics among fastest growing contributor

Market Opportunity

# Breakthrough technology built for strategic advantage

Bio-Native AI: LensAI™ powered by HYFT® technology



Strategic Highlight: Aligned for Growth

# Divestiture completion

This transaction generated approximately **14.3M dollars** in net proceeds

- + Strengthened balance sheet
- + Streamlines global operations under one unified strategy



# Rebrand strengthens market position

**AI. Data. Lab.**  
**One Biointelligence Ecosystem**

Stock Ticker: \$HYFT

Strategic Highlight: Asset Development

# HYFT-enabled research

MindWalk Vault™ Asset

## GLP-1

**Dual-pathway therapeutic** concept that targets metabolic control and health-span mechanisms in parallel



**Current stage:** IND-enabling planning, including pharmacokinetic and toxicology study design and preparation for external *in vivo* collaborations.

Strategic Highlight: Asset Development

# HYFT-enabled research

MindWalk Vault™ Asset

## Dengue Vaccine

LensAI™ identified a highly conserved epitope **across all four dengue virus serotypes** using strict HYFT pattern criteria.



**Current stage:** Advancing preclinical planning, including assay strategy, manufacturing readiness steps and partner engagement for upcoming immunogenicity and neutralization work.

Strategic Highlight: Operations

# Leadership Expansion

Deepening organizational strength



## Chief Financial Officer Scott Areglado

- Leads financial strategy and capital markets execution
- Background: scaling high-growth technology companies
- Enhancing capital access and supporting strategic growth initiatives




## Chief Business Officer Dr. Thomas Lynch

- Leads global platform expansion
- Decades of experience in enterprise commercialization
- Strengthening partner ecosystem and customer footprint

Strategic Highlight: Economic Engine

# Positioning MindWalk for next-phase growth

Strategically built for sustained long-term value creation





IPA and its subsidiaries are now MindWalk

---


# Financial Update

FY 2026 Earnings Presentation

# Q2


# Quarter over Quarter revenue growth

(All values in CAD, in thousands)



# Consistent execution and operating results


(All values in CAD, in thousands)



# Strong cash balance

(All values in CAD, in thousands)

- + Strengthened balance sheet and strategic focus with the divestiture
- + Increased flexibility to allow investments in our Bio-Native AI platform





IPA and its subsidiaries are now MindWalk

---

# Questions

FY 2026 Earnings Presentation

# Q2